AR and prostate cancer: We next computed signalling entropies for 73 CTCs derived from 11 castration resistant prostate cancer patients (CTC-PrCa set, Supplementary Table 1), of which five patients exhibited progression under treatment with enzalutamide (an androgen receptor (AR) inhibitor) (n=36 CTCs), with the other six patients not having received treatment (n=37 CTCs)44.